Loading…
Loading…
ETON does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ETON and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ETON and 80,000+ other tickers.
See exactly how ETON's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ETON and 80,000+ other tickers.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage…
Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,150 shares of the company's stock, valued at approximately $476,000. Other large investors have also
BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,895,833 shares of the company's stock, valued at approximately $68,629,000. BlackRock Inc. owned about 6.92% of Eton Pharmaceuticals at the
Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 144,367 shares of the company's stock after purchasing an additional 39,571 shares
Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,200 shares of the company's stock, valued at approximately $623,000. Bank of Nova Scotia owned about
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.